9776 SAPPORO CLINICAL LABORATORY INC. - Financial Results

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

9776

TSE Standard

SAPPORO CLINICAL LABORATORY INC.

1,960

JPY

ー

(ー%)

Feb 6, 2:20 pm JST

12.51

USD

Feb 6, 12:20 am EST

Result

PTS

outside of trading hours

ー

Summary Chart Historical News Financial Result

Current Period Guidance

Annual

Result

Guidance History

Growth Rate

Profitability

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2022	19,109	1,537	1,605	1,042	306.2	23	May 13, 2022	J-GAAP
Mar, 2023	20,127	1,008	1,159	568	170.5	23	May 12, 2023	J-GAAP
Mar, 2024	19,682	534	514	380	114.1	23	May 13, 2024	J-GAAP
Mar, 2025	20,131	706	707	464	148.4	23	May 12, 2025	J-GAAP
Mar, 2026 Guidance	20,688	775	771	505	161.9	23	May 12, 2025	J-GAAP
YoY	+2.8%	+9.8%	+9.1%	+8.8%	+9.1%

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Mar, 2021	May 13, 2020	17,226	620	635	407	10	J-GAAP
	May 7, 2021	17,502	1,142	1,188	793	23	J-GAAP
Results	May 14, 2021	17,502	1,142	1,188	793	23	J-GAAP
Mar, 2022	May 14, 2021	Available in future release
	May 9, 2022
Results	May 13, 2022
Mar, 2023	May 13, 2022
Results	May 12, 2023
Mar, 2024	May 12, 2023
Results	May 13, 2024
Mar, 2025	May 13, 2024
	May 7, 2025
Results	May 12, 2025
Mar, 2026	May 12, 2025	20,688	775	771	505	23	J-GAAP

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Mar, 2001	8,950	+3.6	Available in future release
Mar, 2002	9,208	+2.9
Mar, 2003	9,310	+1.1
Mar, 2004	9,790	+5.2
Mar, 2005	10,302	+5.2
Mar, 2006	11,413	+10.8
Mar, 2007	11,750	+3.0
Mar, 2008	11,996	+2.1
Mar, 2009	12,559	+4.7
Mar, 2010	14,384	+14.5
Mar, 2011	14,701	+2.2
Mar, 2012	15,536	+5.7
Mar, 2013	15,813	+1.8
Mar, 2014	16,549	+4.7
Mar, 2015	17,166	+3.7
Mar, 2016	17,528	+2.1
Mar, 2017	17,055	-2.7
Mar, 2018	17,459	+2.4
Mar, 2019	17,065	-2.3
Mar, 2020	17,659	+3.5
Mar, 2021	17,502	-0.9
Mar, 2022	19,109	+9.2
Mar, 2023	20,127	+5.3
Mar, 2024	19,682	-2.2
Mar, 2025	20,131	+2.3
Mar, 2026 Guidance	20,688	+2.8	775	+9.8	771	+9.1	161.9	+9.1

Fiscal Year	Revenue	Operating Profit	Operating Profit Margin	ROE	ROA	Total Asset Turnover Ratio	Adj. EPS
Mar, 2024	19,682	534	2.71	3.53	2.29	1.19	114.1
Mar, 2025	20,131	706	3.51	4.20	2.80	1.22	148.4
Mar, 2026 Guidance	20,688	775	3.75	4.40	2.95	1.21	161.9

All-Time High

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	20,131	1,537	1,605	1,042	909.4
Fiscal Year	Mar, 2025	Mar, 2022	Mar, 2022	Mar, 2022	Jun, 1993

Second Half

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2022	10,163	516	570	310	93.1	23	May 12, 2023	J-GAAP
Oct - Mar, 2023	9,820	243	218	154	46.3	23	May 13, 2024	J-GAAP
Oct - Mar, 2024	10,135	369	364	242	77.4	23	May 12, 2025	J-GAAP
Oct - Mar, 2025 Guidance	10,450	396	382	255	81.7	23	Nov 7, 2025	J-GAAP
YoY	+3.1%	+7.3%	+4.9%	+5.4%	+5.6%

Cash Flow

Annual

Fiscal Year	Operating Profit	Fee Cash Flow	Operating Cash Flow	Investing Cash Flow	Financial Cash Flow	Cash & Equivalents	Cash Ratio	Accounting Standards
Mar, 2023	1,008	1,021	1,430	-409	-347	3,654	22.12	J-GAAP
Mar, 2024	534	682	1,077	-395	-369	3,966	23.78	J-GAAP
Mar, 2025	706	-510	730	-1,240	-525	2,931	17.82	J-GAAP

Actual Performance and Financial Trends

Accumulated Results 3rd Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Apr - Dec, 2023	14,852	414	417	311	93.7	81.1	Feb 9, 2024	J-GAAP
Apr - Dec, 2024	15,275	541	553	367	117.2	78.2	Feb 12, 2025	J-GAAP
Apr - Dec, 2025	15,534	559	580	289	92.9	75.2	Feb 6, 2026	J-GAAP
YoY	+1.7%	+3.3%	+4.9%	-21.3%	-20.7%

Quarterly Results

Result

Growth Rate

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Jan - Mar, 2024	4,830	120	97	69	20.7	2.5	May 13, 2024	J-GAAP
Apr - Jun, 2024	4,999	98	102	56	17.9	2.0	Aug 5, 2024	J-GAAP
Jul - Sep, 2024	4,997	239	241	166	53.0	4.8	Nov 8, 2024	J-GAAP
Oct - Dec, 2024	5,279	204	210	145	46.3	3.9	Feb 12, 2025	J-GAAP
Jan - Mar, 2025	4,856	165	154	97	31.0	3.4	May 12, 2025	J-GAAP
Apr - Jun, 2025	5,066	87	93	47	15.3	1.7	Aug 4, 2025	J-GAAP
Jul - Sep, 2025	5,172	292	296	203	65.3	5.6	Nov 7, 2025	J-GAAP
Oct - Dec, 2025	5,296	180	191	39	12.5	3.4	Feb 6, 2026	J-GAAP
YoY	+0.3%	-11.8%	-9.0%	-73.1%	-72.9%

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Jan - Mar, 2021	4,517	+4.7	Available in future release
Apr - Jun, 2021	4,638	+13.8
Jul - Sep, 2021	4,928	+14.9
Oct - Dec, 2021	4,719	+2.1
Jan - Mar, 2022	4,824	+6.8
Apr - Jun, 2022	4,900	+5.6
Jul - Sep, 2022	5,064	+2.8
Oct - Dec, 2022	5,286	+12.0
Jan - Mar, 2023	4,877	+1.1
Apr - Jun, 2023	4,922	+0.4
Jul - Sep, 2023	4,940	-2.4
Oct - Dec, 2023	4,990	-5.6
Jan - Mar, 2024	4,830	-1.0
Apr - Jun, 2024	4,999	+1.6
Jul - Sep, 2024	4,997	+1.2
Oct - Dec, 2024	5,279	+5.8
Jan - Mar, 2025	4,856	+0.5
Apr - Jun, 2025	5,066	+1.3
Jul - Sep, 2025	5,172	+3.5
Oct - Dec, 2025	5,296	+0.3	180	-11.8	191	-9.0	12.5	-73.0

All-Time High Quarterly Results

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	5,296	485	527	381	112.0
Fiscal Year	Dec, 2025	Sep, 2021	Sep, 2021	Mar, 2022	Mar, 2022

Key Balance Sheet Figures

Fiscal Year	BPS	Equity Ratio	Total Asset	Equity	Retained Earnings	Interest-Bearing Debt Ratio	Announce	Accounting Standards
Mar, 2023	3,178.25	64.1	16,521	10,585	9,304	0.23	May 12, 2023	J-GAAP
Mar, 2024	3,283.71	65.6	16,680	10,936	9,607	0.20	May 13, 2024	J-GAAP
Mar, 2025	3,575.27	67.8	16,450	11,153	9,995	0.17	May 12, 2025	J-GAAP
Apr - Dec, 2025	3,675.13	67.0	17,102	11,465	10,213	0.15	Feb 6, 2026	J-GAAP

SAPPORO CLINICAL LABORATORY INC.(9776) Financial Results